Stifel maintains its Buy rating on Novo Nordisk shares, with a target price raised from DKK 950 to DKK 965, after the company announced positive results from a Phase III trial of Mim8 in hemophilia A patients, showing it is competitive with Roche's Hemlibra.

This advance offers Novo Nordisk an opportunity to boost its Rare Diseases franchise, demonstrating that the company is not limited to GLP1 or obesity treatments.

The broker reports that the probability of success for Mim8 has been increased from 50% to 80%, with a filing process scheduled for late 2024 and possible launches around 2025-2026.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.